AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma

Computer-aided detection (CADe) systems using artificial intelligence are improving colonoscopy outcomes by enhancing adenoma detection rates. Meta-analyses indicate a pooled odds ratio of 1.37 for adenoma detection when clinicians integrate algorithmic assistance, with multi-center trials reporting relative increases in detection metrics reaching up to 50%. These AI tools, such as GI Genius and EndoScreener, provide real-time visual alerts to identify mucosal abnormalities during colonoscopies, helping endoscopists spot structural variations in the colon. However, the technology exhibits variability across platforms, with statistical heterogeneity influenced by operator experience and algorithm design. While some systems improve polyp detection with a pooled odds ratio of 1.36, their effectiveness differs based on lesion size and location. Clinical panels confirm an absolute 8% increase in baseline detection metrics but acknowledge low certainty in long-term survival benefits. A key concern is the over-detection of diminutive adenomas—lesions under 5 millimeters—which are often benign. Multi-center trials show that AI-driven gains primarily occur in this low-risk category, raising questions about whether increased detection translates to meaningful patient outcomes. Long-term microsimulations suggest that higher detection rates of small lesions have a negligible impact on 10-year colorectal cancer incidence, highlighting a potential mismatch between clinical metrics and actual risk reduction. The over-reliance on AI alerts may also lead to unnecessary resource expenditure, as clinicians spend time removing and analyzing low-risk polyps. Professional panels note that while detection rates improve, the clinical value of these findings remains uncertain, particularly for long-term survival endpoints. This dilemma underscores the need for balanced integration of AI tools in colonoscopy practices, ensuring efficiency without compromising patient care.